Letrozole

From Glioblastoma Treatments
Revision as of 08:56, 27 March 2024 by Lazy (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search
Property Information
Drug Name Letrozole
FDA Approval Yes (approved for breast cancer; not specifically approved for brain cancer yet)
Used for Experimental for glioblastoma; approved for hormone receptor-positive breast cancer
Clinical Trial Phase Phase 2
Clinical Trial Explanation Not specified
Common Side Effects Hot flashes, joint pain, nausea, increased risk of osteoporosis, fatigue
OS without Not specified
OS with Not specified
PFS without Not specified
PFS with Not specified
Usefulness Rating 3 - Under investigation
Usefulness Explanation Not specified
Toxicity Level 2.5
Toxicity Explanation The treatment's toxicity level is rated at 2.5 out of a possible 5. This suggests that the treatment has some side effects, which can include hot flashes, joint pain, nausea, an increased risk of osteoporosis, and fatigue. However, these side effects are typically manageable and are considered moderate in comparison to other treatments. It's important to note that these side effects may not be experienced by everyone and can vary in intensity from person to person. Also, this drug is still in the experimental phase for glioblastoma and is not yet specifically approved for this type of brain cancer. The exact toxicity could change as more research is done.

Notes: A collaborative study by the University of Cincinnati Cancer Center has initiated a Phase 2 trial to investigate the effectiveness of Letrozole in treating glioblastoma. This follows observations that certain breast cancer drugs, like Letrozole, which is used to treat hormone receptor-positive breast cancer, could be repurposed to inhibit the growth of glioblastoma cells by targeting estrogen receptors. The study is focused on understanding how Letrozole, when combined with standard therapy, affects the progression and treatment outcomes in glioblastoma patients.

Links: [University of Cincinnati article on Phase 2 brain tumor trial with Letrozole](https://www.uc.edu/news/articles/2024/02/collaborative-uc-cancer-center-team-opens-phase-2-brain-tumor-trial.html), [Brain Tomorrow's discussion on breast cancer drug Letrozole for glioblastoma](https://braintomorrow.com/breast-cancer-drug-letrozole-glioblastoma/)

From Ben Williams Book: Not specified

Loading comments...